Clinical Trials Logo

Filter by:
NCT ID: NCT06423625 Completed - Clinical trials for Acute Myocardial Infarction

Hemorrhagic MI Prediction Score Model

MIRON-PREDICT
Start date: June 1, 2023
Phase:
Study type: Observational

Developing a prediction score model for predicting the likelihood of Hemorrhagic MI

NCT ID: NCT06423430 Not yet recruiting - Clinical trials for Treatment Resistant Depression

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

TRANSCEND
Start date: August 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.

NCT ID: NCT06423326 Not yet recruiting - Clinical trials for Stage III Pancreatic Cancer AJCC v8

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic cancer that can be removed by surgery (resectable) or that is borderline resectable. The standard treatment for resectable and borderline resectable pancreatic cancer is a combination of surgery and chemotherapy. Neoadjuvant therapy has been shown to improve overall survival compared to patients receiving surgery first. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel, an antimicrotubule agent that stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel may have fewer side effects and work better than other forms of paclitaxel. Gemcitabine, cisplatin and nab-paclitaxel may be an effective neoadjuvant treatment option for patients with resectable or borderline resectable pancreatic cancer.

NCT ID: NCT06423183 Not yet recruiting - Burn Out Clinical Trials

Interprofessional Mindfulness Practices Advancing Cancer Teamwork

IMPACT
Start date: June 2024
Phase: N/A
Study type: Interventional

The purpose of the research is to understand if mindfulness team training can improve the well-being and teamwork in caring for oncology patients. This study will enroll healthcare professionals in oncology teams, including clinic nurses, nurse managers, medical assistants, social workers, technicians, patient navigators, advanced practice providers, and physicians at UW Madison. Participants will be on study for up to approximately 6 months.

NCT ID: NCT06423053 Active, not recruiting - Mindfulness Clinical Trials

Mindful Physiology: A College Biology Course With Integrated Mindfulness

Start date: March 21, 2024
Phase: N/A
Study type: Interventional

The proposed study aims to evaluate whether integrating mindfulness practice into an undergraduate biology course influences student levels of mindfulness, stress, positive academic emotions, and physical, mental, and social health outcomes. These outcomes will be evaluated for students who enroll in the biology course compared to students who attempted to register but were put on a waitlist (waitlisted).

NCT ID: NCT06422884 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

Start date: September 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in these patient populations.

NCT ID: NCT06422767 Not yet recruiting - Hepatitis B Clinical Trials

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Start date: June 3, 2024
Phase: Phase 1
Study type: Interventional

This study will evaluate the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo. The data generated will be used to model the relationship between bepirovirsen concentration and QTcF.

NCT ID: NCT06422689 Recruiting - Asthma Clinical Trials

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

ANCHOR
Start date: May 10, 2024
Phase: Phase 4
Study type: Interventional

ANCHOR is a prospective, multi-center, phase IV, interventional, single-arm, open-label study of 2,000 adult participants with symptomatic asthma requiring the use of rescue therapy aimed to compare the asthma exacerbation rates before and after switching from albuterol or levalbuterol to albuterol plus budesonide inhalation aerosol as rescue therapy.

NCT ID: NCT06422455 Not yet recruiting - Breast Carcinoma Clinical Trials

Access to Genetic Testing in Underserved Patients With Cancer

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.

NCT ID: NCT06422442 Recruiting - Stuttering, Adult Clinical Trials

Information Processing Biases in Adults Who Stutter

Start date: September 11, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to examine whether stuttering is associated with a tendency to attend more quickly or for longer durations to threat-related information in the environment (threat-related attention bias). The main questions it aims to answer are: Do adults who stutter, relative to adults who do not stutter, attend to threat-related stimuli more than neutral information? Are attentional biases observed across different types of threat or are they specific to threats related to stuttering experiences? Do measures of attention bias explain individual differences in psychological reactions among adults who stutter?